advertisement

Wednesday, February 10, 2010
[an error occurred while processing this directive]

Finasteride

Finasteride (Proscar), which is used to treat benign prostatic hyperplasia (BPH), has been hypothesized to decrease the risk of prostate cancer. (BPH is the noncancerous enlargement of the prostate gland due to an increase in the number of prostate cells.) However, a 2003 study found that although finasteride does appear to reduce the overall risk of prostate cancer, it seems to increase the risk of high-grade prostate cancer. After seven years, 18.4 percent of the men taking finasteride developed prostate cancer, compared with 24.4 percent of men taking a placebo. However, more serious tumors (Gleason score of 7 to 10) occurred in 6.4 percent of the finasteride group, compared with 5.1 percent of the placebo group. Based on these findings, men should not take finasteride solely to prevent prostate cancer, and men taking finasteride for BPH should undergo careful monitoring for cancer.

Multimedia

Health Tips from Dr. Healy:
Video: Why cancer patients should stop smoking

Related Links
Bullet Eight steps you can take to reduce your risk of cancer
Bullet Interested in a clinical trial? Here's all you need to know
Bullet See the top online resources for prostate cancer information
Bullet How to lose weight and keep it off
Bullet Prostate Cancer-Related Clinical Trials Information
0
Email this sectionEmail this pagePrint this sectionPrint this section
0
0
0
Content last updated: 8/15/05Previous PagePrevious page Next Section: SymptomsNext Page



Content excerpted from the Johns Hopkins White Paper on Prostate Disorders.




U.S. News's featured content providers were not involved in the selection of advertisers appearing on this website, and the placement of such advertisement in no way implies that these content providers endorse the products and services advertised. Disclaimer and a note about your health.

advertisement

advertisement

advertisement


Copyright © 2007 U.S.News & World Report, L.P. All rights reserved.

Use of this Web site constitutes acceptance of our Terms and Conditions of Use and Privacy Policy.